A Fresh Shine on Cystic Fibrosis Inhalation Therapy: Antimicrobial Synergy of Polymyxin B in Combination with Silver Nanoparticles

Jasim, Raad; Schneider‐Futschik, Elena K.; Han, Mei‐Ling; Azad, Mohammad Abul Kalam; Hussein, Maytham; Nowell, Cameron J.; Baker, Mark A.; Wang, Jiping; Li, Jian; Velkov, Tony

doi:10.1166/jbn.2017.2355

Cited by 14 publications

(17 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies have associated AgNPs with chloramphenicol, kanamycin, vancomycin, ciprofloxacin, and polymyxin B. In this sense, AgNPs optimize and facilitate the infiltration of antibiotics, allowing maximum efficiency, as well as promoting damage to the microorganism [72][73][74].…”

Section: Antibacterial Activity Of Agnps Against Pseudomonas Aeruginosamentioning

confidence: 99%

Antibacterial and antibiofilm potential of silver nanoparticles against antibiotic-sensitive and multidrug-resistant Pseudomonas aeruginosa strains

et al. 2020

View full text Add to dashboard Cite

Due to the severity of infections caused by P. aeruginosa and the limitations in treatment, it is necessary to find new therapeutic alternatives. Thus, the use of silver nanoparticles (AgNPs) is a viable alternative because of their potential actions in the combat of microorganisms, showing efficacy against Gram-positive and Gram-negative bacteria, including multidrug-resistant microorganisms (MDR). In this sense, the aim of this work was to conduct a literature review related to the antibacterial and antibiofilm activity of AgNPs against antibiotic-sensitive and multidrug-resistant Pseudomonas aeruginosa strains. The AgNPs are promising for future applications, which may match the clinical need for effective antibiotic therapy. The size of AgNPs is a crucial element to determine the therapeutic activity of nanoparticles, since smaller particles present a larger surface area of contact with the microorganism, affecting their vital functioning. AgNPs adhere to the cytoplasmic membrane and cell wall of microorganisms, causing disruption, penetrating the cell, interacting with cellular structures and biomolecules, and inducing the generation of reactive oxygen species and free radicals. Studies describe the antimicrobial activity of AgNPs at minimum inhibitory concentration (MIC) between 1 and 200 μg/mL against susceptible and MDR P. aeruginosa strains. These studies have also shown antibiofilm activity through disruption of biofilm structure, and oxidative stress, inhibiting biofilm growth at concentrations between 1 and 600 μg/mL of AgNPs. This study evidences the advance of AgNPs as an antibacterial and antibiofilm agent against Pseudomonas aeruginosa strains, demonstrating to be an extremely promising approach to the development of new antimicrobial systems.

show abstract

Section: Antibacterial Activity Of Agnps Against Pseudomonas Aeruginosamentioning

confidence: 99%

Antibacterial and antibiofilm potential of silver nanoparticles against antibiotic-sensitive and multidrug-resistant Pseudomonas aeruginosa strains

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The use of synergistic combinations of antibiotics with FDA-approved nonantibiotics has been proposed as a promising alternative to improve the clinical efficacy of polymyxins against these problematic MDR Gram-negative pathogens (13,(15)(16)(17)(18)(19). To date, a number of studies have shown that polymyxin B in combination with FDA-approved nonantibiotics drugs (e.g., ascorbic acid [20], benserazide [20], chloroxine [20], closantel [16], loperamide [21], tamoxifen [17], tegaserod [20], mitomycin C [20], mitotane [19], ivacaftor [15], and silver nanoparticles [18]) display synergistic killing activity against MDR Pseudomonas aeruginosa and Acinetobacter baumannii. However, only several studies investigated the efficacy of polymyxin combinations with nonantibiotic drugs against NDM-producing MDR K. pneumoniae (13,17,18).…”

mentioning

confidence: 99%

“…To date, a number of studies have shown that polymyxin B in combination with FDA-approved nonantibiotics drugs (e.g., ascorbic acid [20], benserazide [20], chloroxine [20], closantel [16], loperamide [21], tamoxifen [17], tegaserod [20], mitomycin C [20], mitotane [19], ivacaftor [15], and silver nanoparticles [18]) display synergistic killing activity against MDR Pseudomonas aeruginosa and Acinetobacter baumannii. However, only several studies investigated the efficacy of polymyxin combinations with nonantibiotic drugs against NDM-producing MDR K. pneumoniae (13,17,18). Zidovudine is a nucleoside reverse transcriptase inhibitor with activity against the human immunodeficiency virus (HIV) (22) and has also been shown to display antibacterial activity against K. pneumoniae (23)(24)(25)(26).…”

mentioning

confidence: 99%

Novel Polymyxin Combination with the Antiretroviral Zidovudine Exerts Synergistic Killing against NDM-Producing Multidrug-Resistant Klebsiella pneumoniae

Rahim

Zhao

et al. 2019

Antimicrob Agents Chemother

Self Cite

View full text Add to dashboard Cite

Polymyxins are used as a last-line therapy against multidrug-resistant (MDR) New Delhi metallo-β-lactamase (NDM)-producingKlebsiella pneumoniae. However, polymyxin resistance can emerge with monotherapy; therefore, novel strategies are urgently needed to minimize the resistance and maintain their clinical utility. This study aimed to investigate the pharmacodynamics of polymyxin B in combination with the antiretroviral drug zidovudine againstK. pneumoniae. Three isolates were evaluated in static time-kill studies (0 to 64 mg/liter) over 48 h. Anin vitroone-compartment pharmacokinetic/pharmacodynamic (PK/PD) model (IVM) was used to simulate humanized dosage regimens of polymyxin B (4 mg/liter as continuous infusion) and zidovudine (as bolus dose thrice daily to achieve maximum concentration of drug in broth [Cmax] of 6 mg/liter) againstK. pneumoniaeBM1 over 72 h. The antimicrobial synergy of the combination was further evaluated in a murine thigh infection model againstK. pneumoniae02. In the static time-kill studies, polymyxin B monotherapy produced rapid and extensive killing against all three isolates followed by extensive regrowth, whereas zidovudine produced modest killing followed by significant regrowth at 24 h. Polymyxin B in combination with zidovudine significantly enhanced the antimicrobial activity (≥4 log10CFU/ml) and minimized bacterial regrowth. In the IVM, the combination was synergistic and the total bacterial loads were below the limit of detection for up to 72 h. In the murine thigh infection model, the bacterial burden at 24 h in the combination group was ≥3 log10CFU/thigh lower than each monotherapy againstK. pneumoniae02. Overall, the polymyxin B-zidovudine combination demonstrates superior antimicrobial efficacy and minimized emergence of resistance to polymyxins.

show abstract

“…In fact, AMPs have been described as synergistic agents with a wide variety of antimicrobials. The inhalation therapy of respiratory infections suffered by cystic fibrosis patients demonstrate strong antimicrobial synergy of Polymyxin B in combination with silver nanoparticles [10]. Moreover, in fungal infections treatment, AMPs are also regarded as candidates to act through synergistic effect with already known antifungals.…”

Section: Antimicrobial Peptide Interactionsmentioning

confidence: 99%

New and old tools to evaluate new antimicrobial peptides

et al. 2018

View full text Add to dashboard Cite

The emergence of antimicrobial resistance due to the overuse of antimicrobials together with the existence of naturally untreatable infections well demonstrates the need for new instruments to fight microbes. Antimicrobial peptides (AMPs) are a promising family of molecules in this regard, because they abundantly occur in nature and the results of preliminary studies of their clinical potential have been encouraging. However, further progress will benefit from the standardization of research methods to assess the antimicrobial properties of AMPs. Here we review the diverse methods used to study the antimicrobial power of AMPs and recommend a pathway to explore new molecules. The use of new methodologies to quantitatively evaluate the physical effect on bacterial biofilms such as force spectroscopy and surface cell damage evaluation, constitute novel approaches to study new AMPs.

show abstract

A Fresh Shine on Cystic Fibrosis Inhalation Therapy: Antimicrobial Synergy of Polymyxin B in Combination with Silver Nanoparticles

Cited by 14 publications

References 0 publications

Antibacterial and antibiofilm potential of silver nanoparticles against antibiotic-sensitive and multidrug-resistant Pseudomonas aeruginosa strains

Antibacterial and antibiofilm potential of silver nanoparticles against antibiotic-sensitive and multidrug-resistant Pseudomonas aeruginosa strains

Novel Polymyxin Combination with the Antiretroviral Zidovudine Exerts Synergistic Killing against NDM-Producing Multidrug-Resistant Klebsiella pneumoniae

New and old tools to evaluate new antimicrobial peptides

Contact Info

Product

Resources

About